Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
出版年份 2020 全文链接
标题
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 22, Issue 1, Pages 74-84
出版商
Elsevier BV
发表日期
2020-12-31
DOI
10.1016/s1470-2045(20)30534-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
- (2020) Laura M Spring et al. LANCET
- Genomic characterization of metastatic breast cancers
- (2019) François Bertucci et al. NATURE
- Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
- (2019) Marina Elena Cazzaniga et al. OncoTargets and Therapy
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
- (2019) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx
- (2019) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
- (2019) H J Burstein et al. ANNALS OF ONCOLOGY
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
- (2016) Tsutomu Takashima et al. LANCET ONCOLOGY
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- 1st International consensus guidelines for advanced breast cancer (ABC 1)
- (2012) F. Cardoso et al. BREAST
- Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
- (2010) Benjamin Chuah et al. CANCER SCIENCE
- Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer
- (2010) Hirose ONCOLOGY REPORTS
- Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial)
- (2009) Yasuo Ohashi et al. BREAST CANCER RESEARCH AND TREATMENT
- Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
- (2009) Y Park et al. BRITISH JOURNAL OF CANCER
- Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial
- (2009) Toru Watanabe et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
- (2008) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now